Release Date: 2024-06-19

Radical Prostatectomy As a Local Therapy in the Management of Patients with Oligometastatic Prostate Cancer

Ferhat Keser (Author), Mehmet Caglar Cakici (Author)

Release Date: 2024-06-19

Oligometastatic prostate cancer can be defined as a narrow number of metastases in the lymph nodes and/or bones, with no visceral organ metastases. It requires precise imaging techniques covering a wide range of diseases. Cytoreductive radical prostatectomy is a method that can be safely applied and well tolerated in a well-selected group of patients and [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inCurrent Management of Metastatic Prostate Cancer
    First Page35
    Last Page43
    DOIhttps://doi.org/10.69860/nobel.9786053359142.3
    Page Count9
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Oligometastatic prostate cancer can be defined as a narrow number of metastases in the lymph nodes and/or bones, with no visceral organ metastases. It requires precise imaging techniques covering a wide range of diseases. Cytoreductive radical prostatectomy is a method that can be safely applied and well tolerated in a well-selected group of patients and can prevent complications due to the progression of local disease. Preliminary results suggest that radical prostatectomy may improve oncological survival in the context of a multimodal treatment approach, while waiting for the results of prospective randomized controlled studies to clarify treatment options.

    Ferhat Keser (Author)
    MD, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital
    https://orcid.org/0000-0002-2803-6481
    3Ferhat Keser completed his undergraduate education at Hacettepe University Faculty of Medicine between 2007 and 2013. He started his professional career in September 2013 as a general practitioner at Sultanbeyli State Hospital Emergency Department and served in this position until June 2015. In July 2016, he started working as a resident in the Department of Urology at Istanbul Medeniyet University and received the title of Urology Specialist in September 2022. He worked as a Urology Specialist at Yüksekova State Hospital from October 2022 to December 2023. In April 2024, he was appointed as a Urology Specialist to Sancaktepe Martyr Prof. Dr. İlhan Varank Training and Research Hospital, where he currently serves. In June 2023, he received the title of Fellow of the European Board of Urology. He has twenty-two articles, sixty-two congress presentations, and four congress presentation awards, three of which are for best presentation, in the field of urology.

    Mehmet Caglar Cakici (Author)
    MD, Associate Professor of Urology, Istanbul Medeniyet University
    https://orcid.org/0000-0002-0176-5887
    3Mehmet Çağlar Çakıcı completed his undergraduate education at Gazi University Faculty of Medicine in 2012. He finished his urology specialization training in 2018 at Ankara Diskapi Yildirim Beyazit Training and Research Hospital. In the same year, he started working as a urology specialist at Istanbul Medeniyet University Goztepe Training and Research Hospital, and he currently continues his work at the same hospital as an associate professor. He has authored over seventy articles and participated as an investigator in ten clinical studies.

    • Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18-e28.

    • Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(1):15-25.

    • Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77(4):508-547.

    • Gandaglia G, Karakiewicz PI, Briganti A, et al. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol. 2015;68(2):325-334.

    • Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36(11):1080-1087.

    • Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352-360.

    • Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216.

    • von Deimling M, Rajwa P, Tilki D, et al. The current role of precision surgery in oligometastatic prostate cancer. ESMO Open. 2022;7(6):100597.

    • Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387-395.

    • Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol). 2010;22(1):46-55.

    • De Visschere PJL, Standaert C, Fütterer JJ, et al. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. Eur Urol Oncol. 2019;2(1):47-76.

    • Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?. BJU Int. 2004;94(3):299-302.

    • Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019;5(6):856-863.

    • Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77(4):403- 417.

    • Zaorsky NG, Calais J, Fanti S, et al. Salvage therapy for prostate cancer after radical prostatectomy. Nat Rev Urol. 2021;18(11):643-668.

    • Perera M, Papa N, Christidis D, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;70(6):926-937.

    • Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9(4):285-293.

    • Kang J, La Manna F, Bonollo F, et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022;530:156-169.

    • Furesi G, Rauner M, Hofbauer LC. Emerging Players in Prostate Cancer-Bone Niche Communication. Trends Cancer. 2021;7(2):112-121.

    • Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315-1326.

    • Tzelepi V, Efstathiou E, Wen S, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011;29(18):2574-2581.

    • Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol. 2020;17(3):168-182.

    • Kadmon D, Heston WD, Fair WR. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol. 1982;127(6):1238-1242.

    • Linxweiler J, Hajili T, Zeuschner P, et al. Primary Tumor Resection Decelerates Disease Progression in an Orthotopic Mouse Model of Metastatic Prostate Cancer. Cancers (Basel). 2022;14(3):737. Published 2022 Jan 31.

    • Niklas C, Saar M, Nini A, et al. Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?. World J Urol. 2021;39(9):3231-3237.

    • Qin XJ, Ma CG, Ye DW, et al. Tumor cytoreduction results in better response to androgen ablation--a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol. 2012;30(2):145-149.

    • Ranasinghe W, Chapin BF, Kim IY, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU Int. 2020;125(6):792-800.

    • Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002;168(3):1008-1012.

    • O’Shaughnessy MJ, McBride SM, Vargas HA, et al. A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology. 2017;102:164-172.

    • Battaglia A, De Meerleer G, Tosco L, et al. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. Eur Urol Oncol. 2019;2(2):174-188.

    • Poelaert F, Verbaeys C, Rappe B, et al. Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial. Urology. 2017;106:146-152.

    • Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832-838.

    • Dai B, Zhang S, Wan FN, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial. Eur Urol Oncol. 2022;5(5):519-525.

    • Sooriakumaran P, Wilson C, Rombach I, et al. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial. BJU Int. 2022;130(1):43-53.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!